TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19363873

Group type: EXPERIMENTAL
Intervention: Topical retinoids (e.g., adapalene, tazarotene)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy (topical retinoids with benzoyl peroxide and/or antibiotics and/or hormonal therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical retinoid monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fixed-combination products (topical retinoid/antimicrobial therapy)
Number of subjects: 0
Study: 17547537

Group type: EXPERIMENTAL
Intervention: teriparatide (20 microg/d)
Number of subjects: 65
Study: 15650348

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 0
Study: 11562516

Group type: COMPARATOR
Intervention: Nitrogen dioxide (NO2) exposure (1.5 parts per million) for 20 minutes
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ascorbic acid supplementation (500 mg twice daily) for 2 weeks
Number of subjects: 30
Study: 9506196

Group type: EXPERIMENTAL
Intervention: ADCON-L gel
Number of subjects: 298

Group type: COMPARATOR
Intervention: Control group (nothing)
Number of subjects: 298
Study: 7821003

Group type: EXPERIMENTAL
Intervention: Potassium dichromate (2.5 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 3133250

Group type: EXPERIMENTAL
Intervention: hMG (human menopausal gonadotropin)
Number of subjects: 40

Group type: COMPARATOR
Intervention: hFSH (human follicle-stimulating hormone)
Number of subjects: 40
Study: 4943605

Group type: EXPERIMENTAL
Intervention: Clofibrate
Number of subjects: 497

Group type: COMPARATOR
Intervention: Corn oil (control)
Number of subjects: 497
Study: 30942033

Group type: EXPERIMENTAL
Intervention: Thumb-tack acupuncture with surrounding needling method plus medication (oral valaciclovir hydrochloride, mecobalamin, vitamin B1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Medication alone (oral valaciclovir hydrochloride, mecobalamin, vitamin B1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Thumb-tack acupuncture with surrounding needling method plus medication
Number of subjects: 60

Group type: COMPARATOR
Intervention: Medication alone
Number of subjects: 60
Study: 28197716

Group type: EXPERIMENTAL
Intervention: Slow Release Insemination (SRI)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard Bolus IUI
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Meta-analysis of SRI
Number of subjects: 50
Study: 25770758

Group type: EXPERIMENTAL
Intervention: High Dairy condition (+4 servings/day of conventional non-fat dairy products)
Number of subjects: 49

Group type: COMPARATOR
Intervention: No Dairy condition (+4 servings/day fruit products)
Number of subjects: 49
Study: 23537477

Group type: EXPERIMENTAL
Intervention: Substance use disorder (SUD) patients at 6 months follow-up
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: SUD patients with ongoing substance use at follow-up
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Patients with onset of SUD before age 16
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Higher frequency of cannabis consumption
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Cannabis use duration
Number of subjects: 323

Group type: COMPARATOR
Intervention: FE-SUD and FE-non-SUD
Number of subjects: 323
Study: 21552059

Group type: COMPARATOR
Intervention: Circular stapler
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Contour-curved stapler
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 198
Study: 19192991

Group type: EXPERIMENTAL
Intervention: Indacaterol 600 microg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Indacaterol 300 microg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Indacaterol 150 microg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 16963194

Group type: EXPERIMENTAL
Intervention: Non-compliant women
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Reasons for non-attendance
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Hurdles faced by willing women
Number of subjects: 469
Study: 14530858

Group type: EXPERIMENTAL
Intervention: NEXAP0 (pressure equal to IAP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: NEXAP-5 (5 cmH(2)O more negative than NEXAP0)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: NEXAP-10 (10 cmH(2)O more negative than NEXAP0)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: NEXAP-10
Number of subjects: 30
Study: 10757255

Group type: EXPERIMENTAL
Intervention: Venlafaxine (titrated to a maximum of 150 mg/day)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Amitriptyline (titrated to a maximum of 150 mg/day)
Number of subjects: 116
Study: 8841216

Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 109

Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 109
Study: 1419551

Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg od)
Number of subjects: 1069

Group type: COMPARATOR
Intervention: Trimethoprim (200 mg bd)
Number of subjects: 1069

Group type: COMPARATOR
Intervention: Co-trimoxazole (trimethoprim 160 mg and sulphamethoxazole 800 mg bd)
Number of subjects: 1069

Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 1069

Group type: COMPARATOR
Intervention: Co-trimoxazole
Number of subjects: 1069

Group type: COMPARATOR
Intervention: Trimethoprim
Number of subjects: 1069
Study: 6362695

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine (2 and 3 ml)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.5% amethocaine (2 and 3 ml)
Number of subjects: 40
Study: 29058057

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcium carbonate
Number of subjects: 0
Study: 27231088

Group type: EXPERIMENTAL
Intervention: Patient emotional status
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Patient physical and emotional status
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Caregiver mood state at baseline
Number of subjects: 299
Study: 24845181

Group type: EXPERIMENTAL
Intervention: Tryptophan (Trp) supplementation for seven days
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo (PLC) intake for seven days
Number of subjects: 118
Study: 22289248

Group type: EXPERIMENTAL
Intervention: Customized exercise tolerance testing (ETT) protocol based on habitual gait speed (HGS)
Number of subjects: 141
Study: 20486336

Group type: EXPERIMENTAL
Intervention: PureZone, a combination therapy involving localized air filtration and pillow encasement
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 19145998

Group type: EXPERIMENTAL
Intervention: levo-bupivacaine
Number of subjects: 112

Group type: COMPARATOR
Intervention: lidocaine
Number of subjects: 112
Study: 11574360

Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg ketamine
Number of subjects: 20

Group type: COMPARATOR
Intervention: 2.5 mg/kg propofol
Number of subjects: 20
Study: 9041875

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 540) received individualized dietary counseling to reduce saturated fat and cholesterol intake.
Number of subjects: 1062

Group type: COMPARATOR
Intervention: Control group (n = 522) received brief dietary counseling according to current practice.
Number of subjects: 1062

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 540)
Number of subjects: 1062

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 1062
Study: 7939487

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Benzodiazepines (most often prescribed)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Supportive psychotherapy (in combination with benzodiazepines)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 3148941

Group type: EXPERIMENTAL
Intervention: 100 micrograms/day selenium for 3 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 150 micrograms selenium per oral administration after two hours of hard training
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo for 3 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo after two hours of hard training
Number of subjects: 18
Study: 31868656

Group type: EXPERIMENTAL
Intervention: Mild electrostimulation using the BodyFlow device for three weeks, five times a day for 20 minutes along with the standard rehabilitation protocol.
Number of subjects: 93

Group type: COMPARATOR
Intervention: Standard rehabilitation protocol after knee arthroscopy (Control group).
Number of subjects: 93
Study: 30507604

Group type: EXPERIMENTAL
Intervention: Organ dose modulation with ASiR-V algorithm
Number of subjects: 300

Group type: COMPARATOR
Intervention: 3D smart mA modulation
Number of subjects: 300
Study: 28737262

Group type: EXPERIMENTAL
Intervention: 7% hypertonic saline (HS) inhaled for 8 hours overnight using the tPAD system
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham treatment (nasal cannula without aerosol)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 7% hypertonic saline (HS) inhaled
Number of subjects: 12
Study: 25310142

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Combination of CBT and pharmacotherapy
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo pill
Number of subjects: 76
Study: 23204506

Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin matrix (PRFM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no PRFM)
Number of subjects: 60
Study: 21480491

Group type: EXPERIMENTAL
Intervention: VTE risk stratification model
Number of subjects: 242738
Study: 18615232

Group type: EXPERIMENTAL
Intervention: Total leg lean mass (TLM)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Reduced muscle strength
Number of subjects: 57

Group type: COMPARATOR
Intervention: Gender
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: TLM and muscle strength correlation
Number of subjects: 57
Study: 16837882

Group type: EXPERIMENTAL
Intervention: letrozole 2.5 mg/day
Number of subjects: 61

Group type: COMPARATOR
Intervention: placebo tablet
Number of subjects: 61
Study: 12625886

Group type: EXPERIMENTAL
Intervention: Patients who received a copy of their GP letter
Number of subjects: 200

Group type: COMPARATOR
Intervention: Patients who did not receive a copy of their GP letter
Number of subjects: 200
Study: 10857519

Group type: EXPERIMENTAL
Intervention: Resistive inspiratory muscle training (RIMT) for 15 to 20 minutes per session, twice per day, 7 days a week for 6 weeks.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided).
Number of subjects: 20
Study: 9663827

Group type: EXPERIMENTAL
Intervention: Bismuth carbomer foam enemas (270 mg elemental bismuth)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo foam enemas
Number of subjects: 40
Study: 8193880

Group type: EXPERIMENTAL
Intervention: Ceftazidime with or without Tobramycin (C +/‐ T)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Ceftazidime plus Piperacillin (C + P)
Number of subjects: 205
Study: 30146645

Group type: EXPERIMENTAL
Intervention: Traditional brackets and Nickel titanium wire
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Damon 3mx brackets and Cu‐NiTi wire
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Traditional brackets and Cu‐NiTi wire
Number of subjects: 45
Study: 28492082

Group type: EXPERIMENTAL
Intervention: Combined Training (CT) - resistance and aerobic training, performed three times a week for 24 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 22
Study: 26282668

Group type: EXPERIMENTAL
Intervention: Prophylactic manual rotation
Number of subjects: 416

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 416
Study: 23011539

Group type: EXPERIMENTAL
Intervention: Factor II G20210A
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Factor V Leiden
Number of subjects: 104
Study: 20132529

Group type: EXPERIMENTAL
Intervention: Sertraline (50‐100 mg/day)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Buspirone (10‐15 mg/day)
Number of subjects: 46
Study: 18436341

Group type: EXPERIMENTAL
Intervention: Telephone brief intervention (2 sessions)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 285
Study: 17132920

Group type: EXPERIMENTAL
Intervention: Serum alpha-fetoprotein (AFP) > or = 20 ng/mL
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Serum alpha-fetoprotein (AFP) > or = 100 ng/mL
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Serum alpha-fetoprotein (AFP) > or = 100 ng/mL with AST <= 2 ULN
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Serum alpha-fetoprotein (AFP) > or = 100 ng/mL with AST > 2 ULN
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Serum alpha-fetoprotein (AFP) > or = 200 ng/mL with AST > 2 ULN
Number of subjects: 117
Study: 14552542

Group type: EXPERIMENTAL
Intervention: Phosphorus magnetic resonance spectroscopy in patients with intermittent claudication
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Phosphorus magnetic resonance spectroscopy in patients with chronic cardiac failure
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Phosphorus magnetic resonance spectroscopy in patients with varicose veins
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Patients with intermittent claudication
Number of subjects: 50
Study: 10791619

Group type: EXPERIMENTAL
Intervention: Oxaceprol (400 mg t.i.d.)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Diclofenac (50 mg t.i.d.)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Oxaceprol
Number of subjects: 263

Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 263
Study: 9348578

Group type: EXPERIMENTAL
Intervention: UFT (tegafur and uracil) 400 mg/day for 1 year after surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study: 8476337

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 3548984

Group type: EXPERIMENTAL
Intervention: Diflunisal (500 to 750 mg/day, twice daily)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Ibuprofen (1,600 to 2,400 mg/day, four times daily)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Diflunisal
Number of subjects: 210

Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 210
Study: 30638029

Group type: EXPERIMENTAL
Intervention: HIV genotypes analysis
Number of subjects: 192
Study: 29311084

Group type: EXPERIMENTAL
Intervention: 250 mg relebactam with 500 mg imipenem-cilastatin, given intravenously every 6 h for 5 doses
Number of subjects: 16
Study: 26846295

Group type: EXPERIMENTAL
Intervention: High pressure pneumoperitoneum (14 mmHg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Low pressure pneumoperitoneum (8 mmHg)
Number of subjects: 50
Study: 23965522

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Plasma Aldosterone Levels
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Caucasian Donor
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 153
Study: 23019005

Group type: EXPERIMENTAL
Intervention: fMRI analysis with musical structure manipulation (scrambling method)
Number of subjects: 0
Study: 22610770

Group type: EXPERIMENTAL
Intervention: Fluency-enhancing therapy
Number of subjects: 30
Study: 17645550

Group type: EXPERIMENTAL
Intervention: Stabilized 0.454% SnF(2)/SHMP dentifrice
Number of subjects: 140

Group type: COMPARATOR
Intervention: Commercially available negative control dentifrice
Number of subjects: 140
Study: 16171667

Group type: EXPERIMENTAL
Intervention: Clonidine (single intravenous dose; 4 microg/kg for patients ≤65 years, 3 microg/kg for patients >65 years)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 50
Study: 12855343

Group type: EXPERIMENTAL
Intervention: Capsaicin 50 microg/ml (0.25, 0.5, 0.75, 1.0, 1.5, 2.0, and 3 ml)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Glycerol (2.5, 5, and 10 ml)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (2.5, 5, and 10 ml)
Number of subjects: 10
Study: 10584888

Group type: EXPERIMENTAL
Intervention: High erythrocyte phosphatidylcholine levels of EPA (upper vs lowest quartile)
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: High erythrocyte phosphatidylcholine levels of DHA (upper vs lowest quartile)
Number of subjects: 797
Study: 9095707

Group type: EXPERIMENTAL
Intervention: Atracurium 0.05 mg/kg followed by succinylcholine 1.5 mg/kg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 50
Study: 1683981

Group type: EXPERIMENTAL
Intervention: 0.5% lignocaine with adrenaline (320,000 dilution)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine with adrenaline (800,000 dilution)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline (80 ml)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No peritoneal administration
Number of subjects: 80
Study: 7065559

Group type: EXPERIMENTAL
Intervention: Metoclopramide, 10 mg orally
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31952131

Group type: EXPERIMENTAL
Intervention: Three dates daily for 16 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (avoided date consumption)
Number of subjects: 100
Study: 31063573

Group type: EXPERIMENTAL
Intervention: Trans-nasal evaporative intra-arrest cooling
Number of subjects: 677

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 677
Study: 29759777

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 582
Study: 27142792

Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg + Ezetimibe 10 mg
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 25128051

Group type: EXPERIMENTAL
Intervention: Detailed information about invasive follow-up testing (colonoscopy)
Number of subjects: 631

Group type: COMPARATOR
Intervention: No information about invasive follow-up testing
Number of subjects: 631
Study: 22011409

Group type: EXPERIMENTAL
Intervention: Supervised aerobic and resistance training plus structured exercise counseling (EXE)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Counseling alone (CON)
Number of subjects: 73
Study: 19293069

Group type: EXPERIMENTAL
Intervention: BNP testing (n = 306)
Number of subjects: 612

Group type: COMPARATOR
Intervention: No testing (n = 306)
Number of subjects: 612
Study: 17470850

Group type: EXPERIMENTAL
Intervention: FLOX (bolus fluorouracil and leucovorin with oxaliplatin)
Number of subjects: 2492

Group type: COMPARATOR
Intervention: FULV (bolus fluorouracil and leucovorin)
Number of subjects: 2492

Group type: EXPERIMENTAL
Intervention: FLOX (oxaliplatin)
Number of subjects: 2492
Study: 15902475

Group type: EXPERIMENTAL
Intervention: Peritoneal taurolidine lavage
Number of subjects: 27

Group type: COMPARATOR
Intervention: Saline peritoneal lavage
Number of subjects: 27
Study: 12056673

Group type: EXPERIMENTAL
Intervention: Cinnarizine 15 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cinnarizine 30 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cinnarizine 45 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Promethazine 10 mg (active control)
Number of subjects: 6
Study: 10509322

Group type: EXPERIMENTAL
Intervention: Postmastectomy radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whole-breast irradiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 0
Study: 7737638

Group type: EXPERIMENTAL
Intervention: EVS + octreotide (100 micrograms three times a day subcutaneously)
Number of subjects: 58

Group type: COMPARATOR
Intervention: EVS alone
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: EVS + octreotide
Number of subjects: 58
Study: 2112339

Group type: EXPERIMENTAL
Intervention: Very early nutrition supplementation (VENS) started immediately after admission (4.4 +/- 0.5 h post-injury)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Very early nutrition supplementation (VENS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (supplementation started after 57.7 +/- 2.6 h post-injury)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 6461679

Group type: EXPERIMENTAL
Intervention: Isotretinoin (1 mg/kg)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Etretinate (1 mg/kg)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Isotretinoin
Number of subjects: 56

Group type: COMPARATOR
Intervention: Etretinate
Number of subjects: 56
Study: 31045769

Group type: EXPERIMENTAL
Intervention: PBMT before and after training sessions + PBMT during detraining
Number of subjects: 0

Group type: COMPARATOR
Intervention: PBMT before and after training sessions + placebo during detraining
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo before and after training sessions + PBMT during detraining
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo before and after training sessions + placebo during detraining
Number of subjects: 0
Study: 27491950

Group type: EXPERIMENTAL
Intervention: Nursing Home Value-Based Purchasing demonstration (intervention)
Number of subjects: 3
Study: 26518765

Group type: EXPERIMENTAL
Intervention: 10 biomarkers added to clinical variables
Number of subjects: 8401

Group type: EXPERIMENTAL
Intervention: 9 biomarkers (including 8 of the 10) added to clinical variables
Number of subjects: 8401

Group type: EXPERIMENTAL
Intervention: 15 biomarkers (including the 10 CV composite biomarkers) added to clinical variables
Number of subjects: 8401

Group type: COMPARATOR
Intervention: Clinical variables alone
Number of subjects: 8401
Study: 24379581

Group type: EXPERIMENTAL
Intervention: Partially covered self‐expandable metal stent (pcSEMS)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Plastic stent (PS)
Number of subjects: 85
Study: 21358485

Group type: EXPERIMENTAL
Intervention: Evidence-based video decision aid
Number of subjects: 2505

Group type: COMPARATOR
Intervention: No video decision aid (Control)
Number of subjects: 2505